A sell-off at this valuation level offers the long-term investor an attractively priced way to buy into a leading diversified healthcare player. Although CVS has some headwinds due to near-term ...

StockNews.com lowered CVS Health from a “hold” rating to a “sell” rating in a research note on Thursday, November 14th. Piper Sandler lowered their price objective on shares of CVS Health ...

CVS Health CVS stock closed at $55.29 on Friday, near its 52-week low of $52.71. The stock has plunged 30% year to date, reflecting the underlying challenges of the retail pharmacy industry. The ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

The latest trading day saw CVS Health (CVS) settling at $44.49, representing a -0.96% change from its previous close. Recently, Zacks.com users have been paying close attention to CVS Health (CVS).

Accordingly, despite the continued dip in share prices, this might not be the ideal time to invest in CVS Health. In fact, those who already own this Zacks Rank #5 (Strong Sell) stock may consider ...

What challenges does CVS face? As the largest pharmacy chain in the U.S., at least 70% of the nation’s population lives within three miles of a CVS store. With this reach, the retailer has the ...

CVS Health Corp., one of the largest U.S. suppliers of prescription drugs, plans to sell the infusion therapy division and 29 related regional pharmacies in the coming months. This is reported in a ...